CoChat

Iatrogenic Cushing’s Syndrome with Osteoporosis and Secondary Adrenal Failure in Human Immunodeficiency Virus-Infected Patients Receiving Inhaled Corticosteroids and Ritonavir-Boosted Protease Inhibitors: Six Cases

Samaras, Katherine, Pett, Sarah, Gowers, Andrew, McMurchie, Marilyn, Cooper, David A. · 2005 · The Journal of Clinical Endocrinology & Metabolism
Cited by 133

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Ritonavir, a protease inhibitor (PI), is a potent inhibitor of cytochrome P450 3A4. This pharmacological effect, even at low doses (≤200 mg/d), is used to “boost” levels of other PIs in the treatment of HIV infection and facilitate once or twice daily dosing with reduced pill burden. Six patients with preexisting HIV-lipodystrophy developed symptomatic Cushing’s syndrome when treated with inhaled fluticasone at varying doses for asthma while concurrently treated with low-dose ritonavir-boosted PI antiretroviral therapy (ART) regimens for HIV infection. There was evidence of adrenal suppression in all patients on stimulation studies. After the withdrawal of inhaled fluticasone, four patients became symptomatic of hypocortisolism, and three required oral corticosteroid support for several months. Other complications included evidence of osteoporosis (n = 3), crush fractures (n = 1), and exacerbation of preexisting type 2 diabetes mellitus (n = 1). In part, the diagnosis of fluticasone-induced Cushing’s syndrome was delayed because all patients had preexisting body composition changes of ART-associated lipodystrophy, masking the Cushing’s features. Practitioners should be aware of the impact on the adrenal axis of coadministration of PI-based ART regimens with inhaled corticosteroids and the potential for exacerbating or even inducing other metabolic conditions, such as osteoporosis or diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2005-0036

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 14

  1. Dybul, 2002, Guidelines for using antiretroviral agents among HIV-infected adults and adolescents, Ann Intern Med, 137, 381, 10.7326/0003-4819-137-5_Part_2-200209031-00001 · DOI · Paper page
  2. Zeldin, 2004, Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients., Antimicrob Chemother, 53, 4, 10.1093/jac/dkh029 · DOI · Paper page
  3. Williams, 2003, National Asthma Education and Prevention Program. Key clinical activities for quality asthma care. Recommendations of the National Asthma Education and Prevention Program., MMWR Recomm Rep, 52, 1
  4. Mollmann, 1998, Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration., Eur J Clin Pharmacol, 53, 459, 10.1007/s002280050407 · DOI
  5. Chen, 1999, Cushing’s syndrome and severe adrenal suppression in patients treated with ritonavir and inhaled nasal fluticasone., Sex Transm Infect, 75, 274
  6. Findlay, 1998, Lesson of the week: childhood Cushing’s syndrome induced by betamethasone nose drops and repeat prescriptions., BMJ, 317, 739, 10.1136/bmj.317.7160.739 · DOI · Paper page
  7. Mollmann, 2001, Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects., J Clin Pharmacol, 41, 1329, 10.1177/00912700122012913 · DOI
  8. Gupta, 2002, Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy, Clin Infect Dis, 35, e69, 10.1086/342562 · DOI · Paper page
  9. Hillebrand-Haverkort, 1999, Ritonavir-induced Cushing’s syndrome in a patient treated with nasal fluticasone., AIDS, 13, 1803, 10.1097/00002030-199909100-00038 · DOI
  10. Rouanet, 2003, Cushing’s syndrome in a patient treated by ritonavir/lopinavir and inhaled fluticasone., HIV Med, 4, 149, 10.1046/j.1468-1293.2003.00149.x · DOI
  11. Clevenbergh, 2002, Iatrogenic Cushing’s syndrome in an HIV-infected patient treated with inhaled corticosteroids (fluticasone propionate) and low dose ritonavir enhanced PI containing regimen., J Infect, 44, 194, 10.1053/jinf.2001.0928 · DOI
  12. Kannisto, 2004, Serum dehydroepiandrosterone sulfate concentration as an indicator of adrenocortical suppression during inhaled steroid therapy in adult asthmatic patients., Eur J Endocrinol, 150, 687, 10.1530/eje.0.1500687 · DOI
  13. Ingelman-Sundberg, 2004, Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms., Naunyn Schmiedebergs Arch Pharmacol, 369, 89, 10.1007/s00210-003-0819-z · DOI · Paper page
  14. Wilson, 2000, Asthma and Cushing’s syndrome., Chest, 117, 593, 10.1378/chest.117.2.593 · DOI

Cited by

See all 133

Metadata

Authors
Samaras, K., Pett, S., Gowers, A., McMurchie, M., & Cooper, D. A.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2005-07-01
Volume
90
Issue
7
Pages
4394-4398
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2077434641
Cited by
133
References
2
FWCI
6.93
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.